About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North. Short name: SEZI.

Press releases

Senzime signs distribution agreement in South Korea

Read more

Senzime signs additional distribution agreements for the TetraGraph

Read more
See all »

News

TetraGraph Poster and Abstract presentation at The Society for Technology in Anesthesia (STA) 2018

Read more

Meet Senzime at Arab Health in Dubai, 29th January – 1st February

Read more

Meet Senzime at WSM in London, 10-12 January

Read more
See all »